Xenetic Biosciences (XBIO) executive compensation, 2025 proxy

James Parslow, Interim Chief Executive Officer & Chief Financial Officer, was paid $481,168 in 2024, up 11% from $433,732 the year before.

Filed
October 31, 2025
Annual meeting
December 11, 2025
Pay year
2024
Named executives
3
CEO total pay
$481,168+11% vs prior year
Former CEO total
$673,143Included $454,559 severance
Former CSO total
$554,083Included $369,994 severance
CEO compensation actually paid
$469,659Calculated under SEC rules
Former CEO compensation actually paid
$622,644Calculated under SEC rules
CEO option grant
20,000 optionsGranted during 2024

How Parslow was paid

$481,168 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary79%Option awards14%All other compensation7%

Named executive officers

ExecutiveTotal
James ParslowInterim Chief Executive Officer & Chief Financial Officer$481,168
Jeffrey F. EisenbergFormer Chief Executive Officer$673,143
Dr. Curtis LockshinFormer Chief Scientific Officer$554,083

What changed and why

  • $481K$481,168 was James Parslow’s 2024 total compensation, up from $433,732 in 2023.
  • $67,280$67,280 in option awards represented Parslow’s only equity compensation in 2024.
  • $471K$471,300 in other compensation for former CEO Jeffrey Eisenberg included $454,559 of severance.
  • $387K$387,091 in other compensation for former Chief Scientific Officer Curtis Lockshin included $369,994 of severance.
  • Strategic, financial and operating performance objectives determined non-equity incentive compensation.
  • 20,000 options were granted to Parslow during 2024.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.